Gantenerumab

Type: Product
Name: Gantenerumab
First reported Jul 28 2014 - Updated 8 hours ago - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons ... [Published Pettinga Financial Advisors - Jul 28 2014]
First reported 19 hours ago - Updated 16 hours ago - 2 reports

MorphoSys highlights pipeline as Q2 shows loss

MorphoSys AG reported a loss for the second quarter due largely to an unfavourable comparison with the previous period when earnings were inflated by a licensing deal with GlaxoSmithKline Plc. However, the company expects its loss for the year as a whole ... [Published MedNous - 16 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Alzheimer’s therapies could result in $12B market by 2023

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.The analysis estimates that the market for Alzheimer’s therapies will more ... [Published MolecularImaging.net - 23 hours ago]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Diabetes Drug Linked to Lower Dementia Risk

COPENHAGEN, Denmark — Long-term use of the diabetes drug pioglitazone ( Actos , Takeda Pharmaceuticals) may protect against dementia, an observational study suggests.The study was presented here at the Alzheimer's Association International Conference ... [Published American Journal of Public Health - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Alzheimer’s Drug Market Predicted to Triple, Reaching Nearly $12 Billion, by 2023

Blockbuster status awaits novel disease-modifying therapiesDecision Resources Group, a health care research firm located in Burlington, Mass., finds that the market for Alzheimer’s disease (AD) therapies will more than triple, reaching nearly $12 billion, ... [Published PT Community - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Roche announces phase II clinical results of crenezumab in Alzheimer’s disease

Details Category: Antibodies Published on Thursday, 17 July 2014 11:33 Hits: 207    Proof of concept study in mild-to-moderate Alzheimer’s disease did not meet its co-primary endpointsPositive trend in cognition observed with greater effect in people ... [Published PipelineReview - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Roche announces phase II clinical results of crenezumab in Alzheimer?s disease

Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer's disease (AD). Although the larger study, known as ... [Published Noodls - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Novartis launches Alzheimer’s prevention study

Novartis announced yesterday it intends to find out if two of its drugs can prevent Alzheimer's disease in people who have a genetic risk of developing the condition.The pharma company will work with Banner Alzheimer's Institute (BAI) on a study involving ... [Published PMLive - Jul 16 2014]
First reported Jun 28 2014 - Updated Jun 28 2014 - 1 reports

Family History Accounts for Some of the Spread in Age at Onset of Familial Alzheimer's

For people who inherit any dominant mutation that causes Alzheimer’s disease, the question is not whether they will develop AD, but when. Now, a meta-analysis that drew both from several large cohorts and from the literature on such families reports that ... [Published Alzheimer Research Forum - Jun 28 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

New Alzheimer's Detection Methods Are on the Horizon

Five million Americans are living with Alzheimer’s disease, an illness that is well known for causing memory loss and erasing cognitive function. But Alzheimer’s is more than just a form of dementia; it’s a fatal disease that the sixth leading cause of ... [Published Grandparents Magazine - Jun 23 2014]
First reported Jun 21 2014 - Updated Jun 21 2014 - 1 reports

Shots on Goal: Call for a New Alzheimer's Drug Discovery Paradigm

Any investor knows that a balanced portfolio offers protection against the inherent risk of the marketplace. Could the same be true for Alzheimer's drug discovery? In a commentary in this week's Science Translational Medicine, Andrew Lo of the Massachusetts ... [Published Alzheimer Research Forum - Jun 21 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

The five most likely ways to beat dementia

Today at the Global Dementia Legacy Event in London, the UK prime minister David Cameron will announce a global push to defeat dementia by 2025, saying: "Dementia now stands alongside cancer as one of the greatest enemies of humanity." These are the most ... [Published New Scientist - Jun 19 2014]

Quotes

"We are pleased with the first half of 2014 and are on track to meet our goals for the full year. With the first-time disclosure of a royalty rate for our HuCAL antibody gantenerumab we are able to provide more visibility on the long-term revenue potential of our partnered compounds" commented Jens Holstein, Chief Financial Officer of MorphoSys AG
"One key goal of this collaboration is for the researchers to make the data from the separate trials more comparable. We believe this will increase the amount that scientists can learn both from each individual trial and from comparing results across the trials" he said
"While AD drug development is understandably focused on disease modification, there exists an important area of additional unmet need for safer, more-effective symptomatic therapies that can control the behavior disturbances associated with later-stage AD,” said Simorellis. “Development in this arena is underway, with clinical trials assessing promising agents like Lundbeck/Otsuka's brexpiprazole for AD-associated agitation."
...is a great need for treatment options," said Richard Scheller, Ph D , Executive Vice President and Head of Genentech Re and Early Development. "These findings support the importance of testing potential disease-modifying agents, such as beta amyloid antibodies, early in the course of the disease."

More Content

All (20) | News (19) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MorphoSys highlights pipeline as Q2 shows loss [Published MedNous - 16 hours ago]
MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014... [Published Seeking Alpha - 19 hours ago]
Alzheimer’s therapies could result in $12B mark... [Published MolecularImaging.net - 23 hours ago]
MorphoSys AG Reports Results for the First Six ... [Published Pettinga Financial Advisors - Jul 28 2014]
Diabetes Drug Linked to Lower Dementia Risk [Published American Journal of Public Health - Jul 24 2014]
Alzheimer’s Drug Market Predicted to Triple, Re... [Published PT Community - Jul 22 2014]
Alzheimer's drug market 'set to triple by 2023' [Published Pharma Times - Jul 22 2014]
Alzheimer's disease market forecast to reach ne... [Published Center Watch - Jul 22 2014]
Roche announces phase II clinical results of cr... [Published PipelineReview - Jul 18 2014]
5 Groundbreaking Drugs That May Prevent Alzheim... [Published Time - Jul 16 2014]
5 Groundbreaking Drugs That May Prevent Alzheim... [Published TIME.com - Jul 16 2014]
Roche announces phase II clinical results of cr... [Published Noodls - Jul 16 2014]
Roche Alzheimer's drug fails main goals in mid-... [Published CNBC - Jul 16 2014]
Novartis launches Alzheimer’s prevention study [Published PMLive - Jul 16 2014]
Can Roche Find Rare Success In Alzheimer's? [Published Motley Fool Discussion Boards - Jul 15 2014]
Family History Accounts for Some of the Spread ... [Published Alzheimer Research Forum - Jun 28 2014]
New Alzheimer's Detection Methods Are on the Ho... [Published Grandparents Magazine - Jun 23 2014]
Shots on Goal: Call for a New Alzheimer's Drug ... [Published Alzheimer Research Forum - Jun 21 2014]
The five most likely ways to beat dementia [Published New Scientist - Jun 19 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
5 Groundbreaking Drugs That May Prevent Alzheim... [Published TIME.com - Jul 16 2014]
At the Alzheimer’s Association International Conference in Copenhagen, scientists described five trials that taking the unprecedented step of testing drugs that may prevent the onset of the neurodegenerative disease in people not yet experiencing cognitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.